Cellectis (NASDAQ:CLLS) Raised to "Hold" at Wall Street Zen

Key Points

• Cellectis has been upgraded to a "hold" rating by analysts at Wall Street Zen, indicating a stable outlook for investors.
• The company reported a loss of $0.24 per share for the last quarter, which was worse than analysts' expectations of a loss of $0.15.
• Institutional investors now own 63.90% of Cellectis, with significant investments from firms like UBS AM and Acadian Asset Management.

Cellectis (NASDAQ:CLLS - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "hold" rating in a note issued to investors on Saturday.

Cellectis Trading Up 5.5%

CLLS traded up $0.19 during trading on Friday, hitting $3.63. The company's stock had a trading volume of 116,370 shares, compared to its average volume of 211,928. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.76. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58. The stock's fifty day moving average price is $2.65 and its 200-day moving average price is $1.85. The firm has a market capitalization of $201.76 million, a P/E ratio of -4.43 and a beta of 3.03.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $18.19 million during the quarter, compared to the consensus estimate of $10.07 million. Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. Analysts anticipate that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CLLS. OLD Mission Capital LLC bought a new stake in shares of Cellectis in the 1st quarter worth approximately $31,000. Acadian Asset Management LLC increased its holdings in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after buying an additional 26,461 shares during the period. Long Focus Capital Management LLC lifted its holdings in shares of Cellectis by 2.2% during the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares in the last quarter. Millennium Management LLC bought a new position in shares of Cellectis during the fourth quarter valued at $962,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock valued at $5,856,000 after acquiring an additional 3,284,409 shares during the last quarter. Institutional investors own 63.90% of the company's stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.